General Information of Drug (ID: DMZNPMQ)

Drug Name
2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
716696
TTD Drug ID
DMZNPMQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
PMID17935984C1 DMO1IHL Pain MG30-MG3Z Clinical trial [4]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [5]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9c) DM0ZRI9 N. A. N. A. Patented [5]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [6]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-13 (MMP-13) TTHY57M MMP13_HUMAN Inhibitor [1]

References

1 Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
2 High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
3 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
4 Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
5 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
6 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
7 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.